We are the Peptide Experts! JPT has a large peptide synthesis capacity, providing over 1 million peptides per year. We offer all possible peptide modifications such as macrocyclic peptides, phosphorylated peptides, labeled and tagged peptides, radioligands, isotope labeling and more. Made in Germany Global Support More than 20 Years of Expertise Ethical, Environmental & Health Standards Portfolio: Custom Peptides Our patented technologies in peptide libraries, pools, microarrays, and micro-scale synthesis set us apart as a leader in the field. From micro to large-scale synthesis, our state-of-the-art labs in Germany deliver peptides tailored to your needs. Modified Peptides We produce modified peptides such as long and stapled peptides, dyes, labeled and biotinylated peptides, PTMs, unique building blocks, conjugations, macrocyclic peptides and more. PepMix Peptide Pools Peptide pools for antigen-specific T-cell stimulation in immune monitoring, assay control, cell therapy development, T-cell expansion etc. In addition to custom PepMix peptide pools we have more than 500 PepMixes in stock, for example: Control Pools: CEFX, CEF, Actin, CMV pp65 … Viral Proteins of EBV, SARS-CoV-2, CMV, VZV, HPV … TAA: Prame, NY-ESO-1, MART-1, MAGE A … Clinical Peptides & Pools Our resulting Clinical Grade Peptides have been approved for a variety of clinical applications including immunotherapy and vaccine development, immune monitoring, and clinical proteomics. Please visit our website for more information! JPT Peptide Technologies GmbH Management: Aurélien Claeyssen, Jens Holstein, Dr. Sierk Poetting Volmerstr. 5 D- 12489 Berlin T: +49 30 6392 5500 peptide@jpt.com https://www.jpt.com/ Registration Court: Berlin / Amtsgericht Charlottenburg, HRB 92692 VAT identification number: DE 814044483 Imprint: https://www.jpt.com/support-contact/corporate/imprint/ Privacy Policy: https://www.jpt.com/support-contact/corporate/privacy-policy/
External link for JPT Peptide Technologies
JPT Peptide Technologies GmbH
Volmerstraße 5
Berlin, 12489, DE
JPT Peptide Technologies reposted this
Gestern beim EliSpot-Workshop in München bei BioNTech SE – eine fantastische Location für einen spannenden Austausch mit großartigen Partnern aus der Branche! 🧪🔬 Vielen Dank an Sylvia Janetzki, Domenico Sauter, Michael Drosch, Dr. Anke Kleiser, Vivien Fritz und Tyler Sandberg, PhD ! Großartig, ein Teil von Euch zu sein! #EliSpot #ZellNet #LifeScience #Networking #Workshop #immunology
𝗢𝘂𝗿 𝗱𝗿𝗲𝗮𝗺-𝘁𝗲𝗮𝗺 𝗶𝗻 𝗴𝗿𝗲𝗲𝗻! 🧬 Yesterday, the ERG ELISpot Ressource Group came together in BioNTech SE's new office spaces in Munich, and gave a free workshop on everything ELISpot! The ERG ELISpot Ressource Group is comprised of Merck Group, Mabtech, ZellNet Consulting and us, yours truly, JPT. Want to connect with us? Do you have more questions on ELISpot? Reach out to either Sylvia Janetzki, Michael Drosch, Gregory P. R. Hansen, PhD, MS, Tyler Sandberg, PhD, Domenico Sauter, Dr. Anke Kleiser and Vivien Fritz & many more! #myjpt #ELISpot #seminar #biontech #merckgroup #zellnet #network
JPT Peptide Technologies reposted this
Gestern beim EliSpot-Workshop in München bei BioNTech SE – eine fantastische Location für einen spannenden Austausch mit großartigen Partnern aus der Branche! 🧪🔬 Vielen Dank an Sylvia Janetzki, Domenico Sauter, Michael Drosch, Dr. Anke Kleiser, Vivien Fritz und Tyler Sandberg, PhD ! Großartig, ein Teil von Euch zu sein! #EliSpot #ZellNet #LifeScience #Networking #Workshop #immunology
🍪 𝗧𝗵𝗶𝘀 𝗼𝗻𝗲 𝗶𝘀 𝗮𝗯𝗼𝘂𝘁 𝗰𝗼𝗼𝗸𝗶𝗲𝘀! 🍪 Our monthly publication series gives you an insight into the role our peptides play in research. Whether for studying diabetes, developing cell therapies, performing T-cell assays or as reference peptides in LS-MS/MS, our peptide tools come in many shapes and formats. Take a look: 📃 𝗨𝘀𝗲 𝗼𝗳 𝗯𝗶𝗼𝘁𝗶𝗻𝘆𝗹𝗮𝘁𝗲𝗱 𝗼𝗹𝗶𝗴𝗼𝗽𝗲𝗽𝘁𝗶𝗱𝗲𝘀 𝘁𝗼 𝘀𝘁𝘂𝗱𝘆 𝘁𝗵𝗲 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗲𝗽𝗶𝘁𝗼𝗽𝗲𝘀 𝗼𝗳 𝗻𝗲𝘄 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝘁𝗵𝗲 𝗽𝗮𝗿𝘁𝗶𝗮𝗹 𝗰𝗮𝗽𝘀𝗶𝗱 𝗼𝗳 𝗵𝗲𝗽𝗮𝘁𝗶𝘁𝗶𝘀 𝘃𝗶𝗿𝘂𝘀 𝗘: Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody Hrabal et al., Scientific Reports (2025) – PMID: 40155491 📃 𝗢𝘂𝗿 𝗣𝗲𝗽𝗠𝗶𝘅 𝗣𝗲𝗽𝘁𝗶𝗱𝗲 𝗽𝗼𝗼𝗹𝘀 𝗰𝗼𝘃𝗲𝗿𝗶𝗻𝗴 𝗖𝗹𝗼𝘀𝘁𝗿𝗶𝗱𝗶𝘂𝗺 𝘁𝗲𝘁𝗮𝗻𝗶, 𝗘𝗽𝘀𝘁𝗲𝗶𝗻-𝗕𝗮𝗿𝗿 𝘃𝗶𝗿𝘂𝘀, 𝗵𝘂𝗺𝗮𝗻 𝗰𝘆𝘁𝗼𝗺𝗲𝗴𝗮𝗹𝗼𝘃𝗶𝗿𝘂𝘀, 𝗮𝗻𝗱 𝗜𝗻𝗳𝗹𝘂𝗲𝗻𝘇𝗮 𝗔 (𝗖𝗘𝗙𝗧 𝗣𝗼𝗼𝗹 & 𝗘𝗙𝗫 𝗨𝗹𝘁𝗿𝗮 𝗦𝘂𝗽𝗲𝗿𝗦𝘁𝗶𝗺 𝗣𝗼𝗼𝗹) 𝘀𝗲𝗿𝘃𝗲 𝗮𝘀 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗰𝗼𝗻𝘁𝗿𝗼𝗹𝘀 𝗶𝗻 𝘁𝗵𝗶𝘀 𝘀𝘁𝘂𝗱𝘆 𝘁𝗼 𝗺𝗼𝗻𝗶𝘁𝗼𝗿 𝘁𝗵𝗲 𝗶𝗺𝗺𝘂𝗻𝗲 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲𝘀 𝗼𝗳 𝗧 𝗰𝗲𝗹𝗹𝘀 𝗳𝗿𝗼𝗺 𝗭𝗜𝗞𝗔 𝘃𝗶𝗿𝘂𝘀 𝗶𝗻𝗳𝗲𝗰𝘁𝗲𝗱 𝗣𝗕𝗠𝗖𝘀: Zika but not Dengue virus infection limits NF-κB activity in human monocyte-derived dendritic cells and suppresses their ability to activate T cells Wang et al., Nature Communications (2025) 📃 𝗧𝗼 𝗱𝗲𝘁𝗲𝗿𝗺𝗶𝗻𝗲 𝘁𝗵𝗲 𝘁𝗼𝘁𝗮𝗹 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗰𝗼𝗻𝘁𝗲𝗻𝘁 𝗼𝗳 𝗰𝗼𝘄’𝘀 𝗺𝗶𝗹𝗸 𝘂𝘀𝗲𝗱 𝗶𝗻 𝗰𝗼𝗼𝗸𝗶𝗲𝘀 𝘃𝗶𝗮 𝗟𝗖-𝗠𝗦/𝗠𝗦, 𝘀𝘁𝗮𝗯𝗹𝗲 𝗶𝘀𝗼𝘁𝗼𝗽𝗲-𝗹𝗮𝗯𝗲𝗹𝗹𝗲𝗱 𝗽𝗲𝗽𝘁𝗶𝗱𝗲𝘀 𝘄𝗶𝘁𝗵 𝘃𝗮𝗿𝘆𝗶𝗻𝗴 𝗹𝗲𝗻𝗴𝘁𝗵𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝗶𝘀𝗼𝘁𝗼𝗽𝗼𝗹𝗼𝗴𝘂𝗲𝘀 𝘄𝗲𝗿𝗲 𝘂𝘀𝗲𝗱 𝗮𝘀 𝗿𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗽𝗲𝗽𝘁𝗶𝗱𝗲𝘀: Food Allergen Quantitative Risk Assessment at a Crossroads: A Critical Evaluation of Laboratory Performance for Quantifying Total Egg and Milk Protein in Cookies Cubero-Leon et al., Foods (2025) Follow our Linkedin account & be on the lookout for our monthly publication posts in the future! #myjpt #jptpaper #pepmix #biotin #hev #zika #positivecontrol #SIL
𝗧𝗵𝗶𝘀 𝗶𝘀 𝘆𝗼𝘂𝗿 𝗹𝗮𝘀𝘁 𝗰𝗵𝗮𝗻𝗰𝗲! 𝗦𝗶𝗴𝗻 𝘂𝗽 𝗻𝗼𝘄! Join us for the free ELISpot Workshop in Munich. Registration deadline is Monday, March 31st. Scan the QR code, or sign up via the link in our comments. For questions reach out to Michael Drosch or Sylvia Janetzki! Merck Group, ZellNet Consulting, Mabtech, BioNTech SE #myjpt #elispot #workshop #seminar #biontech
𝗦𝗲𝗮𝘀𝗼𝗻𝗮𝗹 𝗣𝗲𝗽𝗠𝗶𝘅™ 𝗳𝗼𝗿 𝗦𝗔𝗥𝗦2 & 𝗜𝗻𝗳𝗹𝘂𝗲𝗻𝘇𝗮 & 𝗡𝗼𝗿𝗼𝘃𝗶𝗿𝘂𝘀! We made it through winter and seasonal infection rates are at their peak in the northern hemisphere. Monitoring Influenza and SARS-CoV-2 infections while developing effective vaccines and cell therapies is imperative to minimize the impact of the diseases. Check out our New PepMix™ Peptide Pools via the link below! #norovirus #sars2 #Influenza #pepmix #seasonalinfections #myjpt
𝗜𝘁 𝗶𝘀 𝗪𝗼𝗿𝗹𝗱 𝗧𝘂𝗯𝗲𝗿𝗰𝘂𝗹𝗼𝘀𝗶𝘀 𝗗𝗮𝘆! One part of managing and preventing the spread of the tuberculosis is scientific innovation into therapy and vaccines. With budget cuts affecting said research, and diagnostic services, disease screenings, and surveillance programs slowing down, the WHO – prior to World Tuberculosis Day – called for more immediate resource investment. Despite great successes of reducing infection and mortality rates since 2000, TB has probably returned to being the world’s leading cause of death from a single infectious pathogen. According to the global tuberculosis report 2024, in August, 6 vaccines were in phase III trials. Moreover, addressing drug resistant TB includes new diagnostic approaches and therapy regimens, on top of implementing already existing strategies to implement care directly to patients. 🏥 💉 We contribute on a small level. 🔍 We provide peptides covering common immune response inducing M. Tuberculosis antigens, either in the form of overlapping PepMix peptide pools or single antigens covering immune-dominant epitopes. 🧫 🦠 𝘊𝘰𝘮𝘦 𝘢𝘯𝘥 𝘧𝘪𝘯𝘥 𝘰𝘶𝘵, 𝘣𝘺 𝘤𝘭𝘪𝘤𝘬𝘪𝘯𝘨 𝘰𝘯 𝘵𝘩𝘦 𝘜𝘙𝘓 𝘪𝘯 𝘰𝘶𝘳 𝘤𝘰𝘮𝘮𝘦𝘯𝘵𝘴. 🔎 #myjpt #worldtuberculosisday #tuberculosis #pepmix
🔎 𝘞𝘩𝘢𝘵 𝘥𝘰𝘦𝘴 𝘱𝘦𝘱𝘵𝘪𝘥𝘦 𝘱𝘶𝘳𝘪𝘵𝘺 𝘮𝘦𝘢𝘯 𝘢𝘵 𝘑𝘗𝘛? How to store peptides? How long are they stable? Which quantities can and should i choose? Many questions, many answers! When selecting and customizing your PepMix™ Peptide Pool, you have take many different things into account. Find out what those are in the comment below! #myjpt #pepmix #peptide #protocol
𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗝𝗣𝗧'𝘀 𝗡𝗘𝗪 𝗛𝘆𝗱𝗿𝗼𝗴𝗲𝗹 𝗙𝗼𝗿𝗺𝗶𝗻𝗴 𝗣𝗲𝗽𝘁𝗶𝗱𝗲𝘀! We are expanding our range of peptide categories and are pleased to introduce a new product line to our peptide catalog: 𝘏𝘺𝘥𝘳𝘰𝘨𝘦𝘭 𝘍𝘰𝘳𝘮𝘪𝘯𝘨 𝘗𝘦𝘱𝘵𝘪𝘥𝘦𝘴! 🔴 Among other materials, such hydrogels can be formed via the self-assembly or peptides. The creation of such tunable structures come with broad applications in the fields of tissue engineering, drug delivery, wound healing, and regenerative medicine. 🏥 🚑 💊 💉 ✔️ Find out more in the comment below! #hydrogel #peptides #biomaterials #tissueengineering #drugdelivery
